Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
37.85
79.22
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Hangzhou Tigermed Consulting Co Ltd
Hangzhou Tigermed Consulting Co Ltd
Cost of Revenue
Hangzhou Tigermed Consulting Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Cost of Revenue
-¥4.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-32%
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Cost of Revenue
-¥23.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Cost of Revenue
-¥7.7B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Cost of Revenue
-¥10.5B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Cost of Revenue
-¥1.4B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Cost of Revenue
-¥1.6B
|
CAGR 3-Years
-161%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hangzhou Tigermed Consulting Co Ltd
Glance View
Hangzhou Tigermed Consulting Co., Ltd. is a leading clinical trial and consulting organization based in China, dedicated to facilitating the development of innovative medical therapies. Founded in 2002, the company has rapidly ascended to prominence by leveraging its deep expertise in clinical research while providing comprehensive services that encompass all phases of clinical trials. With a robust portfolio that includes over 4,000 completed projects, Tigermed stands out for its strong focus on quality, efficiency, and regulatory compliance. Serving a diverse clientele of pharmaceutical and biotechnology companies, the firm positions itself as a vital partner in navigating the complexities of the drug development process, particularly in fast-growing Asian markets. An investor looking at Tigermed will find a company that is not only well-established but also poised for significant growth amidst rising global healthcare demands. With a strategic emphasis on expanding its geographic footprint and enhancing technological capabilities, Tigermed is capitalizing on the increasing investment in life sciences, particularly in China and surrounding regions. By harnessing big data analytics and innovative methodologies, the company is well-equipped to streamline clinical operations, reduce costs, and accelerate time-to-market for life-saving treatments. As the global healthcare landscape continues to evolve, Tigermed’s commitment to fostering advancements in clinical research places it in an advantageous position, making it an attractive prospect for investors seeking exposure in the burgeoning healthcare sector.
See Also
What is Hangzhou Tigermed Consulting Co Ltd's Cost of Revenue?
Cost of Revenue
-4.3B
CNY
Based on the financial report for Sep 30, 2024, Hangzhou Tigermed Consulting Co Ltd's Cost of Revenue amounts to -4.3B CNY.
What is Hangzhou Tigermed Consulting Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-32%
Over the last year, the Cost of Revenue growth was 3%. The average annual Cost of Revenue growth rates for Hangzhou Tigermed Consulting Co Ltd have been -23% over the past three years , -24% over the past five years , and -32% over the past ten years .
You don't have any saved screeners yet
